Hepatitis C virus infection and glomerular disease

Minerva Urologica e Nefrologica

Volumn 66, Issue 2, 2014, Pages 139-149

  Fabrizi, F ^a   Donato, F ^a   Messa, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Hepatitis C, chronic; Kidney failure, chronic; Liver diseases

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITUXIMAB; CORTICOSTEROID; INTERFERON; MONOCLONAL ANTIBODY; VIRUS RNA;

ARTICLE; CHRONIC KIDNEY DISEASE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG MECHANISM; GLOMERULOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOGENESIS; PROTEINURIA; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; GENETICS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULUS FILTRATION RATE; HEMATURIA; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; NEPHRITIS, INTERSTITIAL; POSTOPERATIVE COMPLICATION; RENAL INSUFFICIENCY, CHRONIC; VIREMIA; VIROLOGY;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CRYOGLOBULINEMIA; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEMATURIA; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; KIDNEY TRANSPLANTATION; NEPHRITIS, INTERSTITIAL; POSTOPERATIVE COMPLICATIONS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RNA, VIRAL; VIREMIA;

EID: 84908221011     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Pol S, Vallet-Pichard A, Corouge M, Mallet V. Hepatitis C: epidemiology, diagnosis, natural history, and therapy. Contrib Nephrol 2012;176:1-9.
2. Jonson R, Gretch D, Yamabe H, Hart J, Bacchi C, Hartwell P et al. Membranoproliferative glomerulone-phritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
3. Fabrizi F, Pozzi C, Farina M, Dattolo P, Lunghi G, Badalamenti S et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemio-logical and clinical appraisal. Nephrol Dial Transplant 1998;13:1991-7.
4. Fabrizi F, Colucci P, Ponticelli C, Locatelli F. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002;22:309-18.
5. Pascual M, Perrin L, Giostra E, Schifer J. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990;162:567-9.
6. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991;34:1606-10.
7. Agnello V, Chung R, Kaplan L. A role of hepatitis C infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.
8. Fabrizi F, Plaisier E, Saadoun D, Messa P, Martin P, Cacoub P. Hepatitis C virus and kidney: a focus on cryoglobulinemia. Am J Kidney Dis 2013;61:623-37.
9. Cruzado J, Carrera M, Torras J, Grinyo J. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001;1:171-8.
10. Ozdemir B, Ozdemir F, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006;38:492-5.
11. Arase Y, Ikeda K, Murashima N, Chayama K, Tsub-ota A, Koida I et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 1998;37:836-40.
12. Gopalani A, Ahuja T. Prevalence of glomerulopathies in autopsies of patients infected with the hepatitis C virus. Am J Med Sci 2001;322:57-60.
13. El-Serag H, Hampel H, Yeh C, Rabaneck L. Extra-hepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:l439-45.
14. Kidney Disease: Improving Global Outcomes. KDI-GO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008;109:S1-S99.
15. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012;7:549-57.
16. Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C. The impact of hepatitis C virus co-infection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS 2008;22:1799-807.
17. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008;38:775-83.
18. Hofmann J, Tomer A, Chow W, Ye W, Purdue M, Du-berg A. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev 2011;20:326-30.
19. Di Biagio A, Rosso R, Vitale F, Cardinale F, Sormani M, Secondo G et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. Clin Nephrol 2011;75:518-23.
20. Su F, Su C, Chang S, Chen P, Sung F, Lin C et al. Association of hepatitis C virus infection with risk of ESRD: A population-based study. Am J Kidney Dis 2012;60:553-60.
21. Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D et al., for the INSIGHT MART and ESPRIT Study Groups. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012;7:e40245.
22. Peters L, Grint D, Lundgren J, Rockstrosh J, Soriano V, Reiss P et al., for EuroSIDA in EuroCoord. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012;26:1917-26.
23. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P et al. End-stage renal disease and dialysis in HIV-positive patients: observations form a long-term cohort study with a follow-up of 22 years. Hrv Medicine 2013;14:127-35.
24. Cao Y, Gong M, Han Y, Xie J, Li X, Zhang L et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in Mainland China: A multicenter cross-sectional study. Nephrology 2013;18:307-12.
25. Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M et al, for the NA-ACCORD of the IeDEA. Hepatitis C viraemia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013 [Epub ahead of print].
26. Kasuno K, Ono T, Matsumori N, Nogaki F, Kusano H, Watanabe H et al. Hepatitis C virus-associated tubulo-interstitial injury. Am J Kidney Dis 2003;41:707-75.
27. Stehman-Breen C, Alpers C, Couser W, Willson R, Johnson R. Hepatitis C virus-associated membranous glomerulonephritis. Clin Nephrol 1995;44:141-7.
28. Stehman-Breen C, Alpers C, Fleet W, Johnson R. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999;81:37-40.
29. Baid S, Pascual M, Williams W, Tolkoff-Rubin N, Johnson S, Collins B et al. Renal thrombotic micro-angiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999;10:146-53.
30. Markowitz G, Cheng J, Colvin R, Trebbin W, D'Agati V. Hepatitis C viral infection is associated with fibril-lary glomerulonephritis and immunotactoid glomeru-lopathy. J Am Soc Nephrol 1998;9:2244-52.
31. Barsoum R. Hepatitis C virus: from entry to renal injury- facts and potentials. Nephrol Dial Transplant 2007;22:1840-8.
32. Wornle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M et al. Novel role of toll-like receptor 3 in hepatitis C associated glomerulonephritis. Am J Pathol 2006;168:370-85.
33. Choo Q, Kuo G, Werner A, Overby L, Bradley D, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
34. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
35. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi P et al. Interferon alfa-2a therapy in cryoglob-ulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
36. Johnson R, Gretch D, Couser W, Alpers C, Wilson J, Chung M et al. Hepatitis C virus-associated glomerulonephritis: Effect of alpha-interferon therapy. Kidney Int 1994;46:1700-4.
37. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650-71.
38. Gilli P, Stabellini N, Storari A, Gualandi G, Guerra G, Ghinelli F. Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996; 11:526-8.
39. Lopes E, Valente L, Silva A, Kirsztajn G, Cruz C, Ferraz M. Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003;7:353-7.
40. Lo K, Chen C, Lee C. Hepatitis C virus-associated type II mixed cryoglobulinemia vasculitis complicated with membranous proliferative glomerulonepritis. Renal Fail 2009;31:149-52.
41. Orient H, Mathot R, Van Bommel E, Vulto A, Schalm S, Brouwer J. Peg-interferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1. Dig Dis Sci 2005;50:1804-6.
42. Colucci G, Manno G, Grandaliano G, Schena F.P. Cryoglobulinemic membrano-proliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol 2011;75:374-9.
43. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Digest Liver Dis 2000;32:708-15.
44. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Sch-varcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80.
45. Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengat-tini F et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney Int 2003;63:2236-41.
46. Alric L, Plaisier E, Thebault S, Peron J, Rostaing L, Pourrat J et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2004;43:617-23.
47. Saadoun D, Resche-Rigon M, Thibault V, Piette K, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheum 2006;54:3696-706.
48. Roccatello D, Fomasieri D, Giachino O, Rossi D, Bel-trame A, Banfi G et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82.
49. Garini G, Allegri L, Iannuzzella F, Vaglio A, Buzio C. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007;78:5l-9.
50. Abbas G, Hussain S, Shafi T. Effect of antiviral therapy on hepatitis C virus related glomerulopathy. Saudi J Kidney Dis Transplant 2008; 19:775-80.
51. Fabrizi F, Fogazzi G, Cresseri D, Passerini P, Martin P, Messa P et al. Antiviral therapy of HCV-associat-ed cryoglobulinemic glomerulonephritis: Case-report and literature review. Blood Press Kidney Res 2012;35:687-93.
52. Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007;30:212-9.
53. Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C after interferon therapy. Am J Kidney Dis 1999;33:1040-8.
54. Carrion A, Fabrizi F, Martin P. Should ribavirin be used to treat hepatitis C in dialysis patients? Semin Dial 2011;24:272-4.
55. Quartuccio L, Soardo G, Romano G, Zaja F, Scott C, De Marchi G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinae-mia: efficacy and safety in absence of steroids. Rheumatology 2006;45:842-6.
56. Roccatello D, Baldovino S, Rossi D, Giachino O, Man-souri M, Naretto C et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clinic Rev Al-lerg Immunol 2008;34:111-7.
57. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053-6.
58. Fabrizi F, Martin P, Elli A, Montagnino G, Banfi G, Passerini P et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. Int J Artif Organs 2007;30:445-9.
59. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53
60. Sneller M, Hu Z, Langford C. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42.
61. Dammacco F, Tucci F, Lauletta G, Gatti P, De Re V, Conteduca V et al. Pegylated interferon-alpha, riba-virin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53.
62. Saadoun D, Resche Rigon M, Sene D, Terrier B, Kar-ras A, Perard L et al. Rituximab plus peg-interferon-α/ ribavirin compared with peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
63. Saadoun D, Resche Rigon M, Thibault V, Languet M, Pol S, Blanc F et al. Peg-IFNa/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2013 [Epub ahead of print].
64. Perico N, Cattaneo D, Bibkov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. ClinJAm Soc Nephrol 2009;4:207-20.
65. Hestin D, Guillemin F, Castin N, Le Faou A, Cham-pigneulles J, Kessler M. Pre-transplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation 1998;65:741-4.
66. Abrahamian G, Cosimi A, Farrell M, Schoenfeld D, Chung R, Pascual M. Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transplant 2000;6:185-90.
67. Sikaneta T, Williams W, Chung R, Cosimi A, Pascual A. Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation. Transplantation 2002;74:1767-8.
68. Donato F, Banfi G, Cresseri D, Fogazzi B, Martin P, Messa P et al. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: Case-report and literature review. Int J Artif Organs 2013;36:367-72.
69. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007;41:210-20.
70. Pham H, Feray C, Samuel D, Gigou M, Azoulay D, Paradis V et al. Effects of ribavirin on hepatitis C-as-sociated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998;54:1311-9.
71. Hu S, Jaber B. Ribavirin mono-therapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005;63:41-5.
72. Donato F, Fabrizi F, Fogazzi G, Cresseri D, Passerini P, Martin P et al. Remission of HCV-associated glomerulonephritis with pegylated interferon and ribavirin after liver transplantation: case report and literature review. Int J Artif Organs 2013;36:63-8.